Bayer Aktiengesellschaft (ETR:BAYN)
Germany · Delayed Price · Currency is EUR 36.44
+0.11 (0.29%)
At close: Dec 12, 2025
Bayer Aktiengesellschaft Employees
Bayer Aktiengesellschaft had 91,864 employees as of December 31, 2024. The number of employees decreased by 5,067 or -5.23% compared to the previous year.
Employees
91,864
Change (1Y)
-5,067
Growth (1Y)
-5.23%
Revenue / Employee
€518,248
Profits / Employee
€2,237
Market Cap
35.69B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91,864 | -5,067 | -5.23% |
| Dec 31, 2023 | 96,931 | -991 | -1.01% |
| Dec 31, 2022 | 97,922 | 1,972 | 2.06% |
| Dec 31, 2021 | 95,950 | -5 | -0.01% |
| Dec 31, 2020 | 95,955 | -2,782 | -2.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,730 |
| SCHOTT Pharma AG & Co. KGaA | 4,690 |
Bayer Aktiengesellschaft News
- 1 day ago - DCM Shriram shares rally sharply 6% as company signs strategic MoU with Bayer to boost agri-innovation - Business Upturn
- 2 days ago - DCM Shriram and Bayer Crop Science sign strategic MoU to advance sustainable agriculture in India - Business Upturn
- 7 days ago - EQS-News: Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis - Wallstreet:Online
- 7 days ago - Tandem Global e.V. Announces New Supervisory Board Members From AECOM, Bayer, and CRH - Finanz Nachrichten
- 8 days ago - EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 8 days ago - Evotec & Bayer Launch Phase 2 Trial for Alport Syndrome Treatment - Wallstreet:Online
- 8 days ago - EQS-News: Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome - Wallstreet:Online
- 8 days ago - Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome - Business Wire